Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?
Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.